Telmisartan+HCTZ, Hypertension
Information source: Boehringer Ingelheim Pharmaceuticals
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Phase: Phase 4
Status: Recruiting
Sponsored by: Boehringer Ingelheim Pharmaceuticals Official(s) and/or principal investigator(s):
Boehringer Ingelheim Study Coordinator, Study Chair, Affiliation: B.I. Korea Ltd.
Overall contact:
Boehringer Ingelheim Study Coordinator, Email: clintriage@rdg.boehringer-ingelheim.com
Summary
This PMS study aims to review the followings by investigating the actual practice of
MicardisPlus Tablet on the market:
1. Unexpected adverse drug reactions (especially, serious adverse events (SAEs))
2. Frequency of incidence and its change in adverse events (AEs)
3. Factors on the safety profile of the study drug
4. Factors on the efficacy profile of the study drug
Clinical Details
Official title: PMS Study of MicardisPlus Tablet
Study design: N/A
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
patients diagnosed as essential hypertension
n/a
Locations and Contacts
Boehringer Ingelheim Study Coordinator, Email: clintriage@rdg.boehringer-ingelheim.com
Boehringer Ingelheim, Busan, Korea, Republic of; Recruiting
Boehringer Ingelheim, Seoul, Korea, Republic of; Recruiting
Boehringer Ingelheim, Gyeonggido, Korea, Republic of; Recruiting
Boehringer Ingelheim, Gwangju, Korea, Republic of; Recruiting
Boehringer Ingelheim, Daegu, Korea, Republic of; Recruiting
Boehringer Ingelheim, Daejeon, Korea, Republic of; Recruiting
Boehringer Ingelheim, Gangwondo, Korea, Republic of; Recruiting
Boehringer Ingelheim, Incheon, Korea, Republic of; Recruiting
Boehringer Ingelheim, Jeju, Korea, Republic of; Recruiting
Boehringer Ingelheim, Jeonnam, Korea, Republic of; Recruiting
Boehringer Ingelheim, Jeonbuk, Korea, Republic of; Recruiting
Boehringer Ingelheim, Ulsan, Korea, Republic of; Recruiting
Boehringer Ingelheim, Chungnam, Korea, Republic of; Recruiting
Additional Information
Ending date: February 2009
Last updated: October 2, 2008
|
